	, ·	•							•			
· ·									Sheet	1	Of	. 4
	Modified For	m PTO-14	49		Atty. Docke			Sertal		4040		
		RT NE D	EFERENCES CITED BY	V ADDI ICANT	Applicant	A-527E				10/6	45.784	
• /		31 Of R				Feige et al.			<u> </u>			
	IPE		(Use several sheets if necess	ary)	Filing Date	August 18, 2003		Group	)	164 164	29	
( M	R 2 5 2004			U.S. PATE	NT DOCUM							
REAL PROPERTY.	EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE		NAME	CLA	SS	SUB- CLASS		FILING DA' APPROPR	
N. S.	EXAMINER'S INITIALS TRADESIAN	A1	6,331,415	12/18/01	C	abilly et al.	-	_	1			
		A2	5,969,102	10/19/99	8	Bram et al.		L				
		A3	5,922,545	07/13/99	Mat	theakis et al.						•
	t	A4	5,733,731	03/31/98	Se	chatz et al.						
	<b>V</b>	A5	5,514,582	05/07/96	C	apon et al.		$\int$	d			
1		A6-	<b>5,498,530</b>	03/12/96		chatz-et-al.	-	_		_		
white	Si	A7-	5,432,018	07/11/95	D	ower-et-al:-						_
augus (	-	8A	5,338,665	08/16/94	====S	chatz et al				_		
00,449	-	A9==	5,223,409	06/29/93	<u></u>	idner et al.		_		$\mp$		-
Suplicate Spo 14441 8/18/03	How)	A10	6,323,323	11/27/01	Sled	lziewski et al.			1			
			·									
			r							_		

EXAMINER:

Date Considered:

4/15/0 6

EXAMINER: tritial if citation considered, whether or not citation is in conformatice with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 2 Of 4

Modified Form PTO-1449	Atty. Docket No.	Serial No.
	A-527E	10/645.784
LIST OF REFERENCES CITED BY APPLICANT	Applicant	
	Feige et al.	
(Use several sheets if necessary)	Filing Date	Group 35
	August 18, 2003	1642

FOREIGN PATENT DOCUMENTS

EVAMINED® INITIALS		CALIFICAL MICHED	DATE	Mil.	MTOV			~	ACC .	GT,	TO AND	MOTA IS
TO	B1	WO 02/16412	02/28/02	P	СТ	W	ored	+-	_			
Į.	B2√	WO 02/16411	02/28/02	P	CT			1				
	B3 ~	WO 01/85782	11/15/01	. Р	CT							
,	B4 ~	WO 01/02440	01/11/01	Р	CT							
	B5 ✓	WO 00/68378	11/16/00	Р	CT							
,	B6~	WO 00/67034	11/09/00	Р	CT							
	B7	WO 00/47740	08/17/00	Р	CT							
ı	B8 ✓	WO 00/40716	07/13/00	P	CT							
.,	<b>B</b> 9 ✓	WO 00/24782 ~	05/04/00	P	СТ							
7	B10~	WO 99/35170	07/15/99	P	CT							
	B11∙∕	WO 99/25044	05/20/99	P	CT							
	B12~	WO99/12964	03/18/99	P	CT							
	B13-	WO 99/11791	03/11/99	P	CT							
٢	B14~	WO 98/55620	12/10/98	P	CT .							
•	B15/	WO 98/55621	12/10/98	P	T							
,	B16∽	WO 98/27114	06/25/98	P	ŧΤ							
	تB17	WO 98/18921	05/07/98	P	Т			•				
s	B18~	WO 98/15833	04/16/98	P	Т							
,	B19 ✓	WO 96/40987	12/19/96	P	Т	V	'	\	7	V		
1	B20 ~	EP 0 869 180	10/07/98	· Hurle	et al.							
	B21-✓	EP 0 526 452	02/21/01	Capor	n et al.					<del></del>		
		·										
		······					· .					

	Date Considered: 4/15/04
EXAMINER: Initial II citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if communication to applicant.	not in conformance and not considered. Include copy of this form with next

Sheet	3	01_	4

Modified For	m PTO-14	49	Alty. Docket No.	Serial No.			
Trounce To		10	A-527E	10/645.784			
LI	ST OF R	EFERENCES CITED BY APPLICANT	Applicant Feige et al.				
		(Use several sheets if necessary)	Filing Date August 18, 2003	Group 3 ? 16,42			
EXAMINER'S INITIALS		OTHER DOCUMENTS (Including A					
- per	C1 -/	Cwirla <u>et al</u> . (1997), "Peptide Agonithe Natural Cytokine," <i>Science</i> 276:		etin Receptor as Potent as			
<u> </u>	C2 V	Devlin et al. (1990), "Random Peption Binding Molecules," Science 249: 404		of Specific Protein			
	C3 ~	Gross et al. (2000), "TACI and BCM Implicated in B-cell Autoimmune D					
	C4 Gruss et al. (1995), "Tumor Necrosis Factor Ligand Superfamily: Involvement in the Pathology of Malignant Lymphomas," Blood 85(12): 3378-3404.						
6	C5 ~	Hatzoglou et al. (2000), "TNF Recep Associates with TNF Receptor-Asso Activates NF-κB, Elk-1, c-Jun N-Ter Protein Kinase," J. of Immunology 16	ociated Factor (TRAF) minal Kinase, and p3	1, TRAF2, and TRAF3 and			
	C6 V	Khare et al. (2000), "Severe B Cell H 1 Transgenic Mice," PNAS 97(7):337	yperplasia and Autoi	mmune Disease in TALL-			
	C7 ~	Lowman (1997), "Bacteriophage Dis Development," Ann. Rev. Biophys. B					
	C8 ~	Roberts & Szostak (1997), "RNA-Pe Peptides and Proteins," Proc. Natl. A	ptide Fusions for the i Acad. Sci. USA, 94: 122	n vitro Selection of 97-12302.			
	C9 L	Shu et al. (1999), "TALL-1 is a Nove Regulated by Mitogens," J. Leukocyto		Family that is Down-			
ı		Shu et al. (2000), "B Cell Maturation Factor Family Member TALL-1," PM	VAS 97(16):9156-9161.				
1		Smith et al. (1994), "The TNF Receptor Activation, Costimulation, and Deat	th," <u>Cell</u> 76: 959-962.				
ı		Takasaki et al. (1997), "Structure-base Peptidomimetics that Inhibit TNF $lpha$ 1266-1270.	Binding to its Recepto	or," Nature Biotech. 15:			
		Thompson et al. (2000), "BAFF Bind Molecule B Cell Maturation Antiger Peripheral B Cell Population," J. Exp	n and is Important for o. Med. 192(1):129-135.	Maintaining the			
		'Ware (2000), "APRIL and BAFF Cor 192(11): F35-F37.					
	C15 V	Ware (2000), "Decoy Receptors Thw	rart B Cells," Nature 40	04: 949-950.			

EXAMINER:	- 1	1		Date Considered: ,	/
	TO	//		4/15	186
EXAMINER: Initial if citate communication to application	tion considered, whether or not citatio ant.	n is in conformance with MPEP 6	9; Drawline through citation if no	ot in conformance and not considered	I. Include copy of this form with next

·	
EXAMINER:	Date Considered;
T.O. 7	A/15/04
EXAMINER: Initial II citation considered, whether or not citation is in conformance with MPEP 609; Dra communication to applicant.	w line through citation if not in conformance and not considered. Include copy of this form with next

Modified Form PTO-1449	Atty. Docke	A-527F.	Serial No. 10/645,784
LIST OF REFERENCES CITED BY APPLICANT	Applica at	Feige et al	
(Use several sheets if necessary)	Filing Date	August 13, 2003	Group 1635

## **U.S. PATENT DOCUMENTS**

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	C	LASS	SUB CLAS	s	FILING DATE IF APPROPRIATE
the	AA	5,223,409	06/29/93	Ladner et al.	ب	-	_		
1	AB	5,338,665	08/16/94	Schatz et al.					
	AC	5,480,981	01/02/96	Goodwin et al.					
	AD	5,498,530	03/12/96	Schatz et al.					
	AE	5,608,035	03/04/97	Yanofsky et al.					
	AF	5,733,731	03/31/98	Schatz et al.					
	AG	5,739,277	04/14/98	Presta et al.					
	AH	5,767,234	06/16/98	Yanofsky et al.					
	ΑI	5,773,569	06/30/98	Wrighton et al.					
	ĄJ	5,786,331	07/28/98	Barrett et al.					
	AK	5,869,451	02/09/99	Dower et al.					_
	AL	5,869,452	02/09/99	Ng et ai.					
	AM	5,877,151	03/03/99	Pereira Heloise Anne					
	AN	5,880,096	03/09099	Barrett et al.					
	AO	5,922,545	07/13/99	Mattheakis et al.					
	AP	5,932,546	08/03/99	Barrett et al.					
	AQ	5,432,018	07/11/99	Dower et al.					
*	AR	5,945,5075 <u>,432,018</u> .	08/31/99	Mistered Hortelano			V	/	

			_				(	
EXAMINER:	7	· D. of			Date Considered:	36		
			or not citation is in con mmunication to applica	formance with MPEP 60 nt.	9; Draw line through c	itation if n	ot in confort	mance and not

Modified	Form	PTO-1	1449
----------	------	-------	------

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

Atty. Docke	A-527F.	Serial No. 10/6457 War Yer Asstoned
Applica nt	Feige et al	<i>i</i>
Filing Date	August 13, 2003	Group 16 3 9

#### **FOREIGN PATENT DOCUMENTS**

		WAINERL MINNED	NATE	CALITION.	O ACE	CLASS	YES	ATION NO
Tale	ВА	WO 94/07921	04/14/94	per World	)	l		
R	ВВ	WO 95/09917	04/13/95	РСТ				
	вс	WO 95/14714	06/01/95	PCT				
	BD	WO 96/05309	02/22/96	PCT				
	BE	WO 96/11214	04/18/96	PCT				
	BF	WO 96/11953	04/25/96	PCT				
	ВВ	WO 96/17942	06/13/96	PCT				
,	BG	WO 96/18412	06/20/96	PCT				
	ВН	WO 96/30057	10/03/96	PCT				
	BI	WO 96/40772	12/19/96	PCT				
	ВЈ	WO 96/40987	12/19/96	PCT				
	вк	WO 97/00270	01/03/97	PCT				
	BN	WO 97/08203	03/06/97	PCT				
	во	WO 97/08553	03/06/97	PCT				
	BP	WO 97/23614	07/03/97	PCT				
\$	BQ	WO 96/23899	08/08/96	PCT				
7	BR	WO 97/28828	08/14/97	PCT				
.1	BS	WO 97/31019	08/28/97	PCT				
·	ВТ	WO 97/34631	09/25/97	PCT				
	BU	WO 97/35969	10/02/97	PCT				
	BV	WO 97/40070	10/30/97	PCT				
?	BW	WO 97/41220·	04/29/97	PCT				
?	вх	WO 97/44453	11/27/97	PCT				
	BY	WO 98/09985	03/12/98	PCT				
V	BZ	WO 98/10795	03/19/98	PCT V	Ţ	4		

EXAMINER:	T.D	· /	<u> </u>	Date Considered:	4/15/0	<u> </u>
EXAMINER: In	itial if citation co	sidered,	thether or not citation is in conformance with MPEP 60	09; Draw line through	citation if no	t in conformance and not

considered. Include copy of this form with next communication to applicant.

Modified F	Com DTC	LIAAD

### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

Atty. Docke	A-527F.	Serial No.	10/645,784 Not You Assigned
Applica nt	Feige et al		
Filing Date	August 13, 2003	Group //	639

#### **FOREIGN PATENT DOCUMENTS**

		DOM WENT HIMBED	NATE	CAHALBA	MAG	9:	CLASS	TO A MCI	ATTAN QN
TOW	B1	WO 98/15833	04/16/98	per world		-	1		
ń	B2	WO 98/24477	06/11/98	PCT					
	В3	WO 98/28427	07/02/98	PCT					
	B4	WO 98/31820	07/23/98	PCT					
	B5	WO 98/33812	08/06/98	PCT					
	В6	WO 98/46257	10/22/98	PCT					
	В7	WO 98/53842	12/03/98	PCT					11
t	р8	WO 98/55620	12/10/98	PCT					
	В9	WO 99/05302	02/04/99	PCT					
	B10	WO 99/14244	03/25/99	PCT					
	Bii	WO 99/17789	04/15/99	PCT					
	B12	WO 99/18243	04/15/99	PCT					
	B13	WO 99/18781	04/22/99	PCT					
	B14	WO 99/24462	05/20/99	FCT					
ì	B15	WO 00/24782	05/04/00	ECT					
	B16	WO 99/42592	08/26/99	ест					
	B17	WO 99/47151	09/23/99	PCT					
	B18	WO 99/50282	10/07/99	ест					
	B19	WO 99/51254	10/14/99	РСТ					
	B20	WO 99/60013	11/25/99	РСТ					
	B21	WO 99/61476	12/02/99	ст					
	B22	WO 99/62539	1/209/99	РСТ					
	B23	WO 00/00632	01/06/00	ест					
	B24	WO 00/01402	01/13/00	РСТ					
1	B25	WO 00/04048	01/27/00	ест 🗸	*		<b>V</b>		

EXAMINER:		Date Considered:
T-D.	X	4/15-106
EXAMINER: Initial if citation considered, wheth	nef or not citation is in conformance with MPEP 60	9; Draw line through citation if not in conformance and not
considered. Include copy of this form with next	communication to applicant.	

4 af 9

Modified Form PTO-1449

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

Atty. Docke	A-527E	Serial No.	10/645,784 Not You Accounted
Applica nt	Feige et al		
Filing Date	Aumet 13, 2003	Group	1639

#### FOREIGN PATENT DOCUMENTS

		CONTROL MILLIAND	DATE	CARDITON	~ ~	99	CLASS	YES	UNITA I
tow	B26	WO 00/11028	03/02/00	per World	_	-	~	1184	- mx
1	B27	EP 714912	05/06/00	European		ı	}	†	_
<del> </del>	<u> </u>	EP 911393	04/28/99	European				<del>                                     </del>	<del>                                     </del>
V	B29	EP 0 958 829 A1	11/24/99	European	,		V	1	
					<u> </u>	<u>,                                    </u>	<u> </u>	1	
					$\vdash$			1	
								<del>                                     </del>	
	_							1	<u> </u>
								1	
					-			†	<u> </u>
						_		1	
			ļ <del>.</del>						<u> </u>
								1	
								1	
								<b>†</b>	
				<u> </u>				1	
	<u> </u>			-				1	
<del></del>									
	<del>                                     </del>							1	
								1	

EXAMINER:	Date Considered:
1.0.9	4/15/06
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 6	09: Draw line through citation/if not in conformance and not

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation/if not in conformance and not considered. Include copy of this form with next communication to applicant.

MA	,
00	
Nol	

Modified Form PTO-1449	Atty. Docke	A-527F.	Serial No. 10/6451784
LIST OF REFERENCES CITED BY APPLICANT	Applica nt	Feige et al	
(Use several sheets if necessary)	Filing Date	August 13, 2003	16 3 G

	CA	Adey et al. (1996), 'Identification of calmodulin-binding peptide consensus sequences from a phage-displayed random peptide library',  Gene 169:133-134.
	СВ	Adey et al. (1997), 'Isolation of peptides from phage-displayed random peptide libraries that interact with the talin-binding domain of vinculin', Biochem. J. 324:523-528.
	cc	Ahern et al. (1990), 'Special Report: The Peptide-Oligonucleotide Partnership', The Scientist 4 (19):24-25.
	СЭ	Akeson et al. (1996), 'AF12198, a Novel Low Molecular Weight Antagonist, Selectively Binds the Human Type I Interleukin (IL)-1 Receptor and Blocks in vivo Responses to IL-1', J. Biol. Chem. 271:30517-30523.
	CE	Ball et al. (1997), 'Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21 WAF1, Current Biology 7:71-80.
	CF	Barna et al. (1994), "Combination therapy with a synthetic peptide of C-reactive protein and interleukin 2: augmented survival and eradication of pulmonary metastases," Cancer Immunol. Immunother. 38:38-42.
	œ	Bhatnagar et al. (1996), 'Structure-Activity Relationships of Novel Hematoregulatory Peptides', J. Med. Chem. 32:3814-3819.
	СН	Böttger et al. (1997), 'Molecular Characterization of the hdm2-p53 Interaction', J. Mol. Biol. 269:744-756.
	CI	Böttger et al. (1996), 'Identification of novel mdm2 binding peptides by phage display', Oncogene 13:2141-2147.
٠,	ם	Brocks et al. (1997), "A TNF Receptor Antagoistic scFv, Which is Not Secreted in Mammalian Cells, is Expressed as a Soluble Mono- and Bivalent scFv Derivative in Insect Cells," <i>Immunotechnology</i> 3(3): 173-184.
	СК	Burstein et al. (1988), Thymic Humoral Pactor γ2: Purification and Amino Acid Sequence of an Immunoregulatory Peptide from Calf Thymus', <i>Biochemistry</i> 27:4066-4071.
	CL	Capon et al. (1989), 'Designing CD4 Immunoadhesins for AIDS Therapy', Nature 337:525-531.
- ;	СМ	Chan and Kim (1998), "HIV Entry and Its Inhibition" Cell 93:681-684.
	CN	Chirinos-Rojas et al. (1998), 'A Peptidomimetic Antagonist of TNF-o-Mediated Cytotoxicity Identified from a Phage-Displayed Random Peptide Library', Journal of Immunology 161:5621-5626.
	co	Cooper et al. (1987), 'Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients', PNAS 84:8628-8632.
	СР	Cortese et al. (1996), 'Selection of biologically active peptides by phage display of random peptide libraries', Current Opinion in Biotechnology 7:616-621.
	Q	Couet et al. (1997), 'Ideatification of Peptide and Protein Ligands for the Caveolin-scaffolding Domain', The Journal of Biological Chemistry 272 (10):6525-6533.
	CR	Couet et al. (1997), 'Interaction of a Receptor Tyrosine Kinase, EGP-R, with Caveolins', The Journal of Biological Chemistry Vol 272 (48):30429-30438.
	cs	Cuthbertson et al. (1997), 'Design of Low Molecular Weight Hernatoregulatory Agents from the Structure-Activity Relationship of a Dimeric Pentapeptide', J. Med. Chem 40:2876-2882.
	СТ	Cwirla et al. (1997), 'Peptide Agonist of the Thrombopoietin Receptor', Science 276:1696-1699.
	CU	Dedman et al. (1993), 'Selection of Targeted Biological Modifiers from a Bacteriophage Library of Random Peptides', The Journal of Biological Chemistry 268 (31):23025-23030.
	cv	Devlin et al. (1990), 'Random Peptide Libraries: A Source of Specific Protein Binding Molecules', Science 249:404-406.
	cw	Duncan et al. (1988), 'Localization of the binding site for the human high-affinity Fc receptor on IgG', Nature 332:563-564.

EXAMINER: + · O.	Date Considered: 4/15/06
EXAMINER: Initial if citation considered, whether or not citation is in	conformance with MPEP 609; Draw line through citation if not in conformance and not

•		•
ĸ	Λt	a

4	<b>(</b> 1
,	1
⟨	/
V	
1	5
6	Š
٨	

Modified Form PTO-1449	Atty. Docke A-527F.	Serial No. 10/645 754
LIST OF REFERENCES CITED BY APPLICANT	Applica nt Feige et al	
(Use several sheets if necessary)	Filing Date August 13, 20	Group 003 1439

	OTHER DOCUMENTS (including Additor, Title, Date, Pertinent Pages, Etc.)
сх	Dyson et al. (1995), 'Selection of peptide inhibitors of interactions involved in complex protein assemblies: Association of the core and surface antigens of hepatitis B virus', <i>Proc. Natl. Acad. Sci. USA</i> 92:2194-2198.
СҮ	Fahraeus et al. (1996), 'Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from plection in the progression by a 20-residue peptide derived from plection in the progression by a 20-residue peptide derived from plection in the progression by a 20-residue peptide derived from plection in the progression by a 20-residue peptide derived from plection in the progression by a 20-residue peptide derived from plection in the progression by a 20-residue peptide derived from plection in the progression by a 20-residue peptide derived from plection in the progression by a 20-residue peptide derived from plection in the progression by a 20-residue peptide derived from plection in the progression by a 20-residue peptide derived from plection in the progression by a 20-residue peptide derived from plection in the progression by a 20-residue peptide derived from plection in the progression in the progre
cz	Fairbrother et al. (1998), 'Novel Peptides Selected to Bind Vascular Endothelial Growth Factor Target the Receptor-Binding Site', Biochemistry 37:17754-17764.
CI	Fisher et al. (1996), Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein', N. Eng. J. Med. 334(26):1697-1702.
C2	Prancis, Gillian E. (1992), 'Protein modification and fusion proteins', Focus on Growth 3:4-11.
C3	Fukumoto et al. (1998), 'Peptide mimics of the CTLA4-binding domain stimulate T-cell proliferation', Nature Biotechnology, 16:267-270.
C4	Gan et al. (1988), 'Echistatin', <i>JBC</i> 263:19827-19832.
CS	Ghetie et al. (1997), 'Increasing the serum persistence of an IgG fragment by random mutagenesis', Nature Biotechnology 15:637-640.
C6	Gibbs et al. (1994), 'Pharmaceutical Research in Molecular Oncology', Cell 79:193-198.
C7	Gibbs et al. (1994), 'Farnesyltransferase Inhibitors: Ras Research Yields a Potential Cancer Therapeutic', Cell 77:175-178.
C8	Goodson et al. (1994), 'High-affinity urokinase receptor antagonists identified with bacteriophase peptide display', Proc. Natl. Acad. Sci. USA 91:7129-7133.
	Graf and Kastin (1986), "Delta-Sleep-Inducing Peptide (DSIP): An Update" Peptides 7:1165-1187.
C10	Harvill et al. (1995), 'An IgG3-IL2 fusion protein activates complement, binds FcyRI, generates LAK activity and shows enhanced binding to the high affinity IL-2R', Immunotecli. 1:95-105.
C11	Harwig et al. (1994), "Neutrophi Defensins: Purification, Characterization, and Antimicrobial Testing" Methods Enzymology 236:160-172.
C12	Herz et al. (1997), 'Molecular Approaches to Receptors as Targets for Drug Discovery", J. of Receptor & Signal Transduction Research 17(5):671-776.
C13	Hong et al. (1995), 'Protein ligands of the human adenovirus type 2 outer capsid identified by biopanning of a phage-displayed peptide library on separate domains of wild-type and mutant penton capsomers', The EMBO Journal 14:4714-4727.
C14	Hughes, David (1998), 'Therapeutic antibodies make a comeback', Drug Discovery Today 3(10):439-442.
C15	Inagaki-Ohara et al. (1996), 'Effects of a Nonapeptide Thymic Hormone on Intestinal Intraepithelial Lymphocytes in Mice Following Administration of 5-Fluorouracil', Cellular Immunology 17:30-40.
C16	Inglot, Anna D. (1997), 'Classification of Cytokines According to the Receptor Code', Archivum Immunologies et Therapine Experimentalis 45:353-357.
C17	Jefferies, D. (1998), 'Selection of Novel Ligands from Phage Display Libraries: An Alternative Approach to Drug and Vaccine Discovery?, Parasitology Today 14(5):202-206.
CIB	Jefferis et al. (1995), 'Recognition sites on human IgG for Fcy receptors: the role of glycosylation", Immunology Letters 44:111-117.
C19	Jefferis et al. (1990), 'Molecular Definition of Interaction Sites on Human IgG for Fc Receptors (huFcy R)', Molecular Immunology 27(12):1237-1240.

EXAMINER:	Date Considered:			
T. D \	4/15/04			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609	9; Draw line through citation if not in conformance and not			
considered. Include copy of this form with next communication to applicant.				

	4/14	1
	シ	ž
٨	\	
7/7	<b>S</b>	

Modified Form PTO-1449	Atty. Docke	A-527R	Serial No.	10 16 45, 78 C Not You Assistant
LIST OF REFERENCES CITED BY APPLICANT	Applica nt	Feige et al		
(Use several sheets if necessary)	Filing Date	August 13, 2003	Group / (	639

	C20	Johnson et al. (1998), "Identification of a 13 Amino Acid Peptide Mimetic of Erythropoietin and Description of Amino Acids Critical for
İ		the Mimetic Activity of EMP1," Biochemistry 37(11): 3699-3710.
	C21	Jones et al. (1998), 'Stromal Expression of Jagged 1 Promotes Colony Formation by Fetal Hematopoietic Progenitor Cells', Blood 92(5):1505-1511.
	C22	Junghans, R.P. (1997), 'Finally! The Brambell Receptor (FcRB)", Immunologic Research 16(1):29-57.
	CZ3	Kay et al. (1998), 'From peptides to drugs via phage display', DDT 3(8): 370-378.
	C24	King et al. (1991), 'Modulation of Bone Marrow Stromal Cell Production of Colony Stimulating Activity by the Synthetic Peptide', Exp. Hematol. 19:481.
	C25	King et al. (1995), 'Hematoregulatory Peptide, SK&F Induced Stromal Cell Production of KC Enhances CFU-GM Growth and Effector Cell Function', Blood 86(1):309a
	C26	Kitamura et al. (1993), 'Adrenomedullin: A Novel Hypotensive Peptide Isolated from Human Pheochromocytoma', BBRC 192:553-560.
	C27	Kluczyk et al. (1997), 'Immunomodulatory Activity of Oligopeptides Related to Interleukin 1 Receptor Antagonist Sequence', Archivum Immunologiac et Therapiae Experimentalis 45:427-433.
	CZ8	Koivunen et al. (1999), 'Tumor targeting with a selective gelatinase inhibitor', Nature Biotech. 17:768-774.
	C29	Kreeger, Karen Young (1998), 'Immunological Applications Top List of Peptide-Synthesis Services', The Scientist 10(13):19-20.
	C30	Laerum et al. (1988), "The Dimer of Hemoregulatory Peptide (HP5B) Stimulates Mouse and Human Myelopoiesis in vitro", Exp. Hemal. 16:274-280.
	CI	Linse et al. (1997), 'A Region of Vitamin K-dependent Protein S That Binds to C4b Binding Protein (C4BP) Identified Using Bacteriophage Peptide Display Libraries', The Journal of Biological Chemistry 272(23):14658-14665.
	C32	Linsley et al. (1991), 'CTLA-4 is a Second Receptor for the B Cell Activation Antigen B7', J. Exp. Med. 174:561-569.
	<b>C33</b>	Livnah et al. (1996), 'Functional Mimicry of a Protein Hormone by a Peptide Agonist: The EPO Receptor Complex at 2.8 Å', Science 273:464-471.
	C34	Loetscher et al. (1993), "Efficacy of a Chimeric TNFR-IgG Fusion Protein to Inhibit TNF Activity in Animal Models of Septic Shock,"  International Congress Series 2: 455-462.
	C35	Lowman, H.B. (1997), 'Bacteriophage display and discovery of peptide leads for drug development', Annu. Rev. Blophys. Blomol. Struct. 26:401-24.
	C36	Lundergan et al. (1999), "Angiotensin-II increases cytoplasmic calcium, cell number and total DNA for human periodontal ligamental cells in vitro" J. Periodontal Res. 34(4):223-228.
	C37	Martens et al. (1995), 'Peptides which bind to E-selectin and block neutrophil adhesion', <i>The Journal of Biological Chemistry</i> 270(36):21129-21136.
	C38	McGregor, Duncan (1996), 'Selection of proteins and peptides from libraries displayed on filamentous bacteriophage', Molecular Biotechnology 6:155-162.
	C39	Moodie et al. (1994), 'The 3Rs of Llife: Ras, Raf and Growth Regulation', TIG 10(2):44-48.
	C40	Moonga et al. (1998), "Effects of Peptide Fragments of Protein Kinase C on Isolated Rat Osteoclasts" Experimental Physiology 83:717-725.
	C41	Morikis et al. (1998), 'Solution structure of Compstatin, a potent complement inhibitor', Protein Science 7:619-627.

EXAMINER:	+.0.	7	·	Date Considered: 4/15	104
EXAMINER: Initial i considered. Include of	f citation considered, opy of this form with	whether next co	or not citation is in conformance with MPEP 60 mmunication to applicant.	9; Draw line through citation	if not in conformance and not

N FIIT	•
× 75	

Modified Form PTO-1449	Atty. Docke	A-527E	Serial No. 16/645/784 New Yes Assigned
LIST OF REFERENCES CITED BY APPLICANT	Applica nt	Feige et al	
(Use several sheets if necessary)	Filing Date	August 13, 2003	Group 163 G

C42	Naranda et al. (June, 1999), "Activation of erythropoietin receptor in the absence of hormone by a peptide that binds to a domain different from the hormone binding site," <i>Proc. Natl. Acad. Sci. USA</i> 96:7569-7574.
C43	Nishi et al. (1996), Tight-binding inhibitory sequences against pp60° identified using a random 15-amino-acid peptide library', FEBS 399:237-240.
C44	Park et al. (2000), "Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo" Nature  Biotechnology 18:194-198.
C45	Pasquaimi et al. (1996), 'Organ targeting in vivo using phage display peptide libraries', Nature 380:364-366.
C46	Paukovits et al. (1984), 'Structural Investigations on a Peptide Regulating Hemopolesis in vitro and in vivo', Hoppe-Seylers Z Physiol. Chem 364:303-311.
C47	Pawson et al. (1993), 'SH2 and SH3 Domains', Current Biology 3(7):434-442.
C48	Pierce et al. (1995), Identification of cyclized calmodulin antagonists from a phage display random peptide library', Molecular Diversity 1:259-265.
C49	Piette et al. (1997), "Mdm2: keeping p53 under control', Oncogene 15:1001-1010.
Cs0	Powis, Garth (1991), 'Signalling targets for anticancer drug development", TiPS 12:188-194.
CSI	Rickles et al. (1994), Identification of Src, Fyn, Lyn, PI3K and Abl SH3 domain ligands using phage display libraries', The EMBO Journal 13(23):5598-5604.
C52	Rodriguez-Viciana et al. (1994), Phosphatidylinositol-3-OH kinase as a direct target of Ras', Nature 370:527-532.
CS3	Sahu et al. (1996), Inhibition of Human Complement by a C3-Binding Peptide Isolated from a Phage-Displayed Random Peptide Library', The Journal of Immunology 157:884-891.
C54	Sarmay et al. (1992), Mapping and Comparison of the Interaction Sites on the Fc Region of IgG Responsible for Triggering Antibody Dependent Cellular Cytotoxicity (ADCC) Through Different Types of Human Fcy Receptor, Molecular Immunology 29(5):633-639.
CSS	Scott et al. (1990), 'Searching for Peptide Ligands with an Epitope Library', Science 249:386-390.
C56	Siemion et al. (1991), The Evidence on the Possible Interleukin-1 a Tuftsin Competition', Archivum Immunologiae et Therapiae Experimentalis 39:605-611.
CS7	Sparks et al. (1996), 'Distinct ligand preferences of Src homology 3 domains from Src, Yes, Abl, Cortactin, p53bp2, PLCY, Crk, and Grb2', Proc. Natl. Acad. Sci. USA 93:1540-1544.
C58	Sparks et al. (1994), Identification and Characterization of Src SH3 Ligands from Phage-displayed Random Peptide Libraries', The Journal of Biological Chemistry 269(39):23853-23856.
CS9	Stauffer et al. (1997), Inhibition of Lyn Function in Mast Cell Activation by SH3 Domain Binding Peptides', Biochemistry 36:9388-9394.
C60	Suzuki and Yoshino (1992), "The Relationship Between Amino Acid Sequences of Sperm-Activating Peptides and the Taxonomy of Echinoids" Comp. Biochem. Physiol. 102B:679-690.
C61	Takasaki et al. (1997), Structure-based design and characterization of exocyclic peptidomimetics that inhibit TNFα binding to its receptor', Nature Biotechnology 15:1266-1270.
C62	Van Zee et al. (1996), Protection Against Lethal Escherichia coli Bacteremia in Baboons (Papio anubis) by Pretreatment with a 55-kDa TNF Receptor (CD120a)-Ig Fusion Protein, Ro 45-2081; J. Immunol. 156:2221-2230.

$+$ $0.$ $\sim$	l	/' -	106
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 60 considered. Include copy of this form with next communication to applicant.	9; Draw line through o	itation	if not in conformance and not

•		•

	;	/
	1	į
	100	
人とこ	\ \ \ \ \	

Modified Form PTO-1449	Atty. Docke A-527E	Serial No. 10/645784
LIST OF REFERENCES CITED BY APPLICANT	Applica nt Feige et al	
(Use several sheets if necessary)	Filing Date August 13, 2003	Group /C35

	C63	Wells et al. (1992), 'Rapid evolution of peptide and protein binding properties in vivo', Current Opinion of Biotechnology 3:355-362.
	C64	Whitty et al. (1996), Small molecule cytokine mimetics', Chemistry & Biology 6:R107-R118.
	C&S	Wieczorek et al. (1994), The Immunomodulatory Activity of Tetra- and Tripeptides of Tuftsin-Kentsin Group', Peptides 15(2):215-221.
	C66	Wieczorek et al. (1997), 'A Hexapeptide VTKFYF from C-Terminal Part of Interleukin-1 Receptor Antagonist, an Inhibitor of IL-1 - IL-1 Receptor Interaction', Polish Journal of Pharmacology 49:107-117.
	C67	Wilson et al. (1998), Phage display: applications, innovations, and issues in phage and host biology', Can. J. Microbiol. 44:313-329.
	C68	Wrighton et al. (1997), Increased potency of an erythropoietin peptide mimetic through covalent dimerization', Nature Biotechnology 15:1261-1265.
	C69	Wrighton et al. (1996), 'Small Peptides as Potent Mimetics of the Protein Hormone Erythropoietin', Science 273:458-463.
	C70	Yanofsky et al. (1996), 'High Affinity type I interleukin 1 receptor antagonists discovered by screening recombinant peptide libraries', PNAS 93:7381-7386.
	CJ.	Yoshida et al. (1984), The Activity of Synthetic analogs of Serum Thymic Factor (FTS) to Convert Mouse Pre-T Cells into Thy-1 Positive Cells', Int. J. Immunopharmac. 6(2):141-146.
	C72	Yu et al. (1994), 'Structural Basis for the Binding of Proline-Rich Peptides to SH3 Domains', Cell 76:933-945.
	C73	Zheng et al. (1995), 'Administration of Noncytolytic IL-10/Pc in Murine Models of Lipopolysaccharide-Induced Septic Shock and Allogeneic Islet Transplantation', J. Immunol. 154:5590-5600.
	C74	Ishikawa et al (1998), 'GD1α-replica peptides functionally mimic GD1α, an adhesion molecule of metastatic tumor cells, and suppress the tumor metastasis', FEBS 441:20-24.
	C75	Krast et al. (1999), Definition of an Unexpected Ligand Recognition Motif for ανβ6 Integrin', Journal of Biological Chemistry 274(4):1979-1985.
	C76	Maurer et al. (1997), 'Autodisplay: One-Component System for Efficient Surface Display and Release of Soluble Recombinant Proteins from escherichia coli', ournal of Bacteriology 179(3):794-80.
·		
		·

EXAMINER:		Date Considered: 4/15/06	
EXAMINER: Initial if citation considered, whether not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			